Document is current
Any future updates will be listed below
-
Authors
Wyles, Saranya P.
Yu, Grace T.
Ganier, Clarisse
Tchkonia, Tamar
Lynch, Magnus D.
Kuchel, George A.
Kirkland, James L.
-
Funding
Funding for this research was provided by:
Hevolution Foundation (HF-GRO-23-1199252-26, HF-GRO-23-1199148-3)
Foundation for the National Institutes of Health (GM145408, P30AG067988, U54AG075941, R37AG13925, R33AG61456, R01AG072301)
Canadian Institutes of Health Research
Connor Fund
Robert J. and Theresa W. Ryan
Noaber Foundation
Wellcome Trust (211276/E/18/Z)
Mary Kay Inc. (1128845)
- License Information
-
More Information
Article History
Received: 30 January 2025
Accepted: 10 February 2025
First Online: 25 February 2025
Declarations
:
: This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic conflict of interest policies. Consent to participate was not applicable as no new clinical data were obtained in this study.
: Not applicable.
: ML is co-founder of Fibrodyne Ltd, a company working on fibroblast cell therapies. The authors have no other conflicts of interests to disclose.
